Alk Inhibitor | List of Frontiers open access articles

Case Report

Published on 24 Feb 2023

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

in Neuro-Oncology and Neurosurgical Oncology

Shubin W. Shahab
Matthew Schniederjan
Jose Velazquez Vega
Stephen Little
Andrew Reisner
Tobey MacDonald
Dolly Aguilera

Frontiers in Oncology

doi 10.3389/fonc.2023.1123378

5,432 views
13 citations

Mini Review

Published on 30 Nov 2016

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

in Pathology

Phu N. Tran
Samuel J. Klempner

Frontiers in Medicine

doi 10.3389/fmed.2016.00065

8,643 views
10 citations

Case Report

Published on 24 Feb 2022

Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature

in Pathology

Qianqian Han
Xin He
Lijuan Cui
Yan Qiu
Yuli Li
Huijiao Chen
Hongying Zhang

Frontiers in Medicine

doi 10.3389/fmed.2022.826705

3,974 views
15 citations

Case Report

Published on 15 Oct 2019

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors

in Cancer Genetics

Elena Poddubskaya
Alexey Bondarenko
Alexander Boroda
Evgenia Zotova
Alex Glusker
Svetlana Sletina
Luidmila Makovskaia
Philipp Kopylov
Marina Sekacheva
Alexey Moisseev

Frontiers in Oncology

doi 10.3389/fonc.2019.01026

5,582 views
21 citations

Original Research

Published on 27 Feb 2020

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells

in Molecular and Cellular Oncology

Jingqiu Wang
Jing-Quan Wang
Chao-Yun Cai
Qingbin Cui
Yuqi Yang
Zhuo-Xun Wu
Xingduo Dong
Leli Zeng
Linguo Zhao
Dong-Hua Yang

Frontiers in Oncology

doi 10.3389/fonc.2020.00228

5,509 views
26 citations

Case Report

Published on 06 Mar 2024

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib

in Blood Cancer

Dan Liu
Lijie Xing
Hui Wang
Ping Li
Haichen Wei

Frontiers in Hematology

doi 10.3389/frhem.2024.1334577

2,659 views
3 citations

Case Report

Published on 28 Jan 2026

Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report

in Cancer Molecular Targets and Therapeutics

Zhigang Fu
Gengda Huang
Jian Xie
Li Luo
Qinqin Ren
Hong He
Yuan Wang
Jiexia Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1680523

521 views

Original Research

Published on 01 May 2025

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

in Thoracic Oncology

Guangming Tian
Jun Nie
Ling Dai
Weiheng Hu
Jie Zhang
Di Wu
Xiangjuan Ma
Xiaoling Chen
Sen Han
Jindi Han

Frontiers in Oncology

doi 10.3389/fonc.2025.1577607

4,717 views
5 citations

Case Report

Accepted on 23 Feb 2026

Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

in Cancer Molecular Targets and Therapeutics

JESUS GUSTAVO YARINGAÑO CERNA
Jorge Hernando
Alejandro García-Álvarez
Carmela Iglesias-Felip
Carles Zafón
Ana Vivancos
María Roca-Herrera
Sergio Pérez-Fernández
Sandra Martínez-Badal
Belén Elguero

Frontiers in Oncology

Original Research

Published on 05 Jul 2019

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

in Pediatric Oncology

Muhammad Wasi Alam
Marcus Borenäs
Dan E. Lind
Diana Cervantes-Madrid
Ganesh Umapathy
Ruth H. Palmer
Bengt Hallberg

Frontiers in Oncology

doi 10.3389/fonc.2019.00579

11,472 views
38 citations

Case Report

Published on 01 Nov 2023

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

in Thoracic Oncology

Qin Chen
Jingjing Zhang
Xuan Wang
Wenkang Zong
Leina Sun
Jianwen Qin
Yan Yin

Frontiers in Oncology

doi 10.3389/fonc.2023.1227980

3,900 views
11 citations

Case Report

Accepted on 02 Feb 2026

Case report: Cerebellar ALK+ ALCL: Diagnostic Challenges and Therapeutic Innovation

in Neuro-Oncology and Neurosurgical Oncology

Zengfang Hao
Xuhan Wang
Zhihong Gao
Lan Yang

Frontiers in Oncology

Case Report

Published on 18 Jun 2025

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development

in Molecular and Cellular Oncology

Silvan Hofmann
Claudine Egger
Silke Potthast
Martin Zoche
Andreas Wicki
Tarun Mehra

Frontiers in Oncology

doi 10.3389/fonc.2025.1613235

2,134 views

Case Report

Published on 25 Feb 2025

Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review

in Thoracic Oncology

Hao Zhang
Wei Xia
Yifan Zhang
Shihao Bao
Jingtong Zeng
Xianjie Li
Bo Zhang
Hanqing Wang
Song Xu
Zuoqing Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1474997

3,167 views
4 citations

Case Report

Published on 25 Feb 2022

Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis

in Molecular and Cellular Oncology

Zaixiang Fu
Ganggui Zhu
Liquan Wang
Shen Hu
Lu Cheng
Fuyi Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.823813

3,345 views
12 citations

Review

Published on 06 Apr 2022

Targeting ALK Rearrangements in NSCLC: Current State of the Art

in Thoracic Oncology

Ling Peng
Liping Zhu
Yilan Sun
Justin Stebbing
Giovanni Selvaggi
Yongchang Zhang
Zhentao Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.863461

25,561 views
72 citations

Articles

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib

Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

Case report: Cerebellar ALK+ ALCL: Diagnostic Challenges and Therapeutic Innovation

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development

Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review

Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis

Targeting ALK Rearrangements in NSCLC: Current State of the Art